Advisor Group Inc. grew its position in shares of Zoetis Inc. (NYSE:ZTS) by 42.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,809 shares of the company’s stock after purchasing an additional 7,954 shares during the quarter. Advisor Group Inc.’s holdings in Zoetis were worth $1,710,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of ZTS. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Zoetis by 16.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after purchasing an additional 230 shares in the last quarter. Harfst & Associates Inc. increased its holdings in shares of Zoetis by 16.1% during the 2nd quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock valued at $117,000 after purchasing an additional 260 shares in the last quarter. Almanack Investment Partners LLC. purchased a new position in shares of Zoetis during the 2nd quarter valued at approximately $119,000. Peddock Capital Advisors LLC purchased a new position in shares of Zoetis during the 2nd quarter valued at approximately $140,000. Finally, Parallel Advisors LLC increased its holdings in shares of Zoetis by 41.1% during the 2nd quarter. Parallel Advisors LLC now owns 2,263 shares of the company’s stock valued at $141,000 after purchasing an additional 659 shares in the last quarter. 92.44% of the stock is owned by hedge funds and other institutional investors.
A number of research firms recently issued reports on ZTS. Cantor Fitzgerald set a $75.00 price target on shares of Zoetis and gave the company a “buy” rating in a research note on Monday, August 14th. Cowen and Company set a $80.00 price target on shares of Zoetis and gave the company a “buy” rating in a research note on Friday. The Goldman Sachs Group, Inc. reissued a “neutral” rating and issued a $62.00 price target on shares of Zoetis in a research note on Monday, August 7th. Stifel Nicolaus reissued a “buy” rating and issued a $65.00 price target on shares of Zoetis in a research note on Friday, July 21st. Finally, BidaskClub cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, September 20th. One analyst has rated the stock with a sell rating, five have given a hold rating and twelve have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $67.65.
Shares of Zoetis Inc. (NYSE ZTS) opened at $70.79 on Friday. Zoetis Inc. has a one year low of $48.55 and a one year high of $71.12. The company has a current ratio of 2.80, a quick ratio of 1.95 and a debt-to-equity ratio of 2.45. The stock has a market cap of $34,310.00, a price-to-earnings ratio of 32.06, a price-to-earnings-growth ratio of 2.04 and a beta of 1.02.
Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.63 by $0.02. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The company had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.32 billion. During the same quarter in the previous year, the company posted $0.52 EPS. The firm’s quarterly revenue was up 8.5% on a year-over-year basis. sell-side analysts forecast that Zoetis Inc. will post 2.37 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Thursday, November 9th will be paid a dividend of $0.105 per share. The ex-dividend date is Wednesday, November 8th. This represents a $0.42 annualized dividend and a yield of 0.59%. Zoetis’s dividend payout ratio (DPR) is presently 22.11%.
COPYRIGHT VIOLATION WARNING: This story was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://stocknewstimes.com/2017/11/18/advisor-group-inc-purchases-7954-shares-of-zoetis-inc-zts.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.